Prognostic value of advanced lung cancer inflammation index in head and neck squamous cell carcinoma

  • Bernhard J. Jank
  • Lorenz KadletzEmail author
  • Julia Schnöll
  • Edgar Selzer
  • Christos Perisanidis
  • Gregor Heiduschka
Head & Neck



The advanced lung cancer inflammation index (ALI) is a useful tool for prediction of outcome in several malignancies. However, to date, its significance in head and neck cancer patients has not been evaluated.


We retrospectively analyzed data from 93 patients who were diagnosed with head and neck squamous cell carcinoma (HNSCC) and treated with surgical resection and postoperative radiotherapy between 2002 and 2012. The aim of this study was to investigate whether the preoperative ALI is a prognostic indicator for disease-free survival and overall survival in HNSCC patients.


A low ALI was significantly associated with a worse 5-year disease-free survival (47.0 vs. 83.5%, p < 0.001), and overall survival (44.4 vs. 73.6%, p = 0.008). Multivariate analysis showed that low ALI was independently associated with disease-free survival (p < 0.001) and overall survival (p = 0.02).


The ALI could serve as an easily available prognostic indicator for disease-free and overall survival prediction in patients with HNSCC.


Head and neck squamous cell carcinoma Advanced lung cancer inflammation index Disease-free survival Overall survival Recurrence risk Precision medicine 



This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.

Ethical approval

The institutional research board approved this study (EK 1311/2018)

Informed consent

Informed consent was obtained from all patients to use their clinical data for a scientific purpose.


  1. 1.
    Gatta G et al. (2015) Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur J Cancer 51: 2130CrossRefGoogle Scholar
  2. 2.
    Pulte D, Brenner H (2010) Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 15:994CrossRefGoogle Scholar
  3. 3.
    Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357:539CrossRefGoogle Scholar
  4. 4.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646CrossRefGoogle Scholar
  5. 5.
    Todoric J, Antonucci L, Karin M (2016) Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res 9:895CrossRefGoogle Scholar
  6. 6.
    Piemonte ED, Lazos JP, Brunotto M (2010) Relationship between chronic trauma of the oral mucosa, oral potentially malignant disorders and oral cancer. J Oral Pathol 39:513Google Scholar
  7. 7.
    Gomez D et al (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32:1757CrossRefGoogle Scholar
  8. 8.
    Jafri SH, Shi R, Mills G (2013) Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer 13:158CrossRefGoogle Scholar
  9. 9.
    Liu G, Ke LC, Sun SR (2018) Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: a meta-analysis. Medicine 97:e12176CrossRefGoogle Scholar
  10. 10.
    Ma M et al (2018) Prognostic value of inflammatory biomarkers in gastric cancer patients and the construction of a predictive model. Digest Surg. Google Scholar
  11. 11.
    Ohno Y (2018) Role of systemic inflammatory response markers in urological malignancy. Int J Urol 26(1):31–47CrossRefGoogle Scholar
  12. 12.
    JM Riedl et al (2017) Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting. Oncotarget 8:96048Google Scholar
  13. 13.
    Sun W et al (2016) Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: neutrophil–lymphocyte ratio and platelet–lymphocyte ratio. Head Neck 38(Suppl 1):E1332CrossRefGoogle Scholar
  14. 14.
    Tanaka N et al. (2015) Impact of combined use of blood-based inflammatory markers on patients with upper tract urothelial carcinoma following radical nephroureterectomy: proposal of a cumulative marker score as a novel predictive tool for prognosis. Eur Urol Focus 1:54CrossRefGoogle Scholar
  15. 15.
    Selzer E, Grah A, Heiduschka G, Kornek G, Thurnher D, (2015) Primary radiotherapy or postoperative radiotherapy in patients with head and neck cancer: Comparative analysis of inflammation-based prognostic scoring systems. Strahlentherapie Onkologie 191:486CrossRefGoogle Scholar
  16. 16.
    Park YH, Yi HG, Lee MH, Kim CS, Lim JH (2017) Prognostic value of the pretreatment advanced lung cancer inflammation index (ALI) in diffuse large B cell lymphoma patients treated with R-CHOP chemotherapy. Acta haematologica 137:76CrossRefGoogle Scholar
  17. 17.
    Feng JF, Huang Y, Chen QX (2014) A new inflammation index is useful for patients with esophageal squamous cell carcinoma. OncoTargets Therapy 7:1811CrossRefGoogle Scholar
  18. 18.
    Turri-Zanoni M et al (2017) Prognostic value of pretreatment peripheral blood markers in paranasal sinus cancer: Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio. Head Neck 39:730CrossRefGoogle Scholar
  19. 19.
    DK Salim et al (2015) Neutrophil to lymphocyte ratio is an independent prognostic factor in patients with recurrent or metastatic head and neck squamous cell cancer. Mol Clin Oncol 3:839CrossRefGoogle Scholar
  20. 20.
    Moon H et al (2016) Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy. Radiother Oncol 118:330CrossRefGoogle Scholar
  21. 21.
    Takenaka Y et al (2015) Prognostic significance of body mass index before treatment for head and neck cancer. Head neck 37(Oct):1518CrossRefGoogle Scholar
  22. 22.
    McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12:223CrossRefGoogle Scholar
  23. 23.
    Shiroyama T et al (2018) Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med 7:13CrossRefGoogle Scholar
  24. 24.
    He X et al (2015) Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer 16:e165CrossRefGoogle Scholar
  25. 25.
    Tomita M, Ayabe T, Maeda R, Nakamura K (2017) Combination of advanced lung cancer inflammation index and C-reactive protein is a prognostic factor in patients with operable non-small cell lung cancer. World J Oncol 8:175CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Otorhinolaryngology and Head and Neck SurgeryMedical University of ViennaViennaAustria
  2. 2.Department of Oral and Maxillofacial SurgeryUniversity of AthensAthensGreece
  3. 3.Department of Radiation OncologyMedical University of ViennaViennaAustria

Personalised recommendations